Kidney & Urology Foundation of America
Kidney & Urology Foundation of America
SAVE THE DATE:
Support Walk the Walk
New York Walk the Walk

October 31, 2010 - Central Park
REGISTER ONLINE NOW!
join us on Facebook
Join KUFA today
and become an essential part of the fight to save and improve lives. There are no fees for patients, family and friends to get connected!

 

Patient Resources

FDA Approved Drugs » Therapeutic Areas

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

FDA Approved Drugs by Therapeutic Area

Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Click on an area below to view the complete list of drugs in that category or review descriptions for our therapeutic area list to assist you in your search.

Find out more about the types of drugs included in this listing.

FDA Approved Drugs for Hematology

Drugs Approved in 2014

Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Biogen Idec; For the treatment of hemophilia B, Approved March 2014

Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014

Drugs Approved in 2013

Gazyva (obinutuzumab); Genentech; For the treatment of previously untreated chronic lymphocytic leukemia, Approved October of 2013

Imbruvica (ibrutinib); Pharmacyclics; For the treatment of mantle cell lymphoma, Approved November of 2013

Injectafer (ferric carboxymaltose injection); Luitpold Pharmaceuticals; For the treatment of iron deficiency anemia, Approved July 2013

Kcentra (Prothrombin Complex Concentrate); CSL Behring; For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency, Approved May 2013

Nymalize (nimodipine); Arbor Pharmaceuticals; For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013

Pomalyst (pomalidomide); Celgene; For the treatment of relapsed and refractory multiple myeloma, Approved February 2013

Ravicti (glycerol phenylbutyrate); Hyperion Therapeutics; For the treatment of pediatrics and adults with urea cycle disorders, Approved February 2013

Revlimid (lenalidomide); Celgene; For the treatment of mantle cell lymphoma, Approved June 2013

Rixubis (Coagulation Factor IX (Recombinant)]; Baxter International; For the routine prophylaxis and control of hemophilia B, Approved June 2013

Tretten (Coagulation Factor XIII A-Subunit [Recombinant]); Novo Nordisk; For the treatment of congenital factor XIII (FXIII) A-subunit deficiency, Approved December of 2013

Valchlor (mechlorethamine) gel; Ceptaris Therapeutics; For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma, Approved August 2013

Drugs Approved in 2012

Bosulif (bosutinib); Pfizer; For the treatment of Ph+ chronic myelogenous leukemia, Approved September 2012

Elelyso (taliglucerase alfa); Pfizer; For the treatment of Gaucher disease, Approved May 2012

Iclusig (ponatinib); Ariad Pharmaceuticals; For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Approved December 2012

Kyprolis (carfilzomib); Onyx Pharmaceuticals; For the treatment of multiple myeloma, Approved July 2012

Marqibo (vinCRIStine sulfate LIPOSOME injection); Talon Therapeutics; For the treatment of Ph- acute lymphoblastic leukemia, Approved August 2012

Neutroval (tbo-filgrastim); Teva Pharmaceutical; For the reduction in the duration of severe chemotherapy-induced neutropenia, Approved August 2012

Omontys (peginesatide); Affymax; For the treatment of anemia due to chronic kidney disease, Approved March 2012

Synribo (omacetaxine mepesuccinate); Teva Pharmaceutical; For the treatment of chronic or accelerated phase chronic myeloid leukemia, Approved October 2012

Drugs Approved in 2011

Adcetris (brentuximab vedotin); Seattle Genetics; For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma, Approved August 2011

Erwinaze (asparaginase Erwinia chrysanthemi); Eusa Pharma; For the treatment of acute lymphoblastic leukemia, Approved November of 2011

Ferriprox (deferiprone); Apotex; For the treatment of transfusional iron overload due to thalassemia, Approved October 2011

Jakafi (ruxolitinib); Incyte; For the treatment of myelofibrosis, Approved November 2011

Soliris (eculizumab); Alexion; For the treatment of atypical hemolytic uremic syndrome, Approved September 2011

Xarelto (rivaroxaban); Bayer; For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011

Drugs Approved in 2010

Vpriv (velaglucerase alfa for injection); Shire Pharmaceuticals; For the treatment of type 1 Gaucher disease, Approved March 2010

Drugs Approved in 2009

Arzerra (ofatumumab); GlaxoSmithKline; For the treatment of chronic lymphocytic leukemia, Approved October 2009

Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics; For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009

Efient (prasugrel); Eli Lilly; for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009

Elitek (rasburicase); sanofi-aventis; For the management of plasma uric acid levels in adults with malignancies, Approved October 2009

Feraheme (ferumoxytol); AMAG; For the treatment of iron deficiency anemia associated with chronic kidney disease, Approved June 2009

Folotyn (pralatrexate injection); Allos Therapeutics; For the treatment of peripheral T-cell lymphoma, Approved September 2009

Istodax (romidepsin); Gloucester Pharmaceuticals; For the treatment of cutaneous T-cell lymphoma, Approved November 2009

Samsca (tolvaptan); Otsuka; For the treatment of hyponatremia, Approved May of 2009

Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human); Octapharma; For the treatment of von Willebrand disease, Approved December of 2009

Drugs Approved in 2008

Mozobil (plerixafor injection); Genzyme; For the treatment of non-Hodgkin’s lymphoma and multiple myeloma, Approved December 2008

Nplate (romiplostim); Amgen; For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura, Approved August 2008

Promacta (eltrombopag); GlaxoSmithKline; For the treatment of thrombocytopenia, Approved November 2008

Drugs Approved in 2007

Kuvan (sapropterin dihydrochloride); BioMarin Pharmaceuticals; For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria, Approved December 2007

Mircera (methoxy polyethylene glycol-epoetin beta); Roche; For the treatment of anemia associated with chronic renal failure, Approved November 2007

Soliris (eculizumab); Alexion; For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007

Drugs Approved in 2006

Dacogen (decitabine); MGI Pharma; For the treatment of both treatment-naïve and -experienced Myelodysplastic Syndromes, Approved May 2006

Drugs Approved in 2005

Revlimid (lenalidomide); Celgene; For the treatment of low- and intermediate-1-risk myelodysplastic syndromes, Approved December 2005

Drugs Approved in 2004

Vidaza (azacitidine); Pharmion Corporation; For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias, Approved May 2004

Drugs Approved in 2003

Bexxar; Corixa; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse, Approved June 2003

Levitra (vardenafil); Bayer, GlaxoSmithKline; For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003

Reyataz (atazanavir sulfate); Bristol-Myers Squibb; For the treatment of HIV-1 infection in combination with other antiretroviral agents, Approved July 2003

Zemaira (alpha1-proteinase inhibitor); Aventis Behring; For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema, Approved July 2003

Drugs Approved in 2002

Neulasta; Amgen; Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy, Approved January 2002

Drugs Approved in 2001

Arixtra; Organon, Sanofi-Synthelabo; Injectable solution for the prevention of deep vein thrombosis, Approved December 2001

Drugs Approved in 2000

Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham; Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000

Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company; For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000

Kogenate FS (Antihemophilic Factor Recombinant); Bayer; For the treatment of hemophilia A, Approved June 2000

Renagel (sevelamer hydrochloride); Genzyme; For the control of serum phosphorus in patients with chronic kidney disease on dialysis, Approved July of 2000

Venofer (iron sucrose injection); Luitpold Pharmaceuticals; For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis, Approved November 2000

Drugs Approved in 1999

Aggrenox; Boehringer Ingelheim; Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke, Approved November 1999

Busulflex; Orphan Medical; For use in combination for the treatment of leukemia, Approved February 1999

Ferrlecit; R&D Laboratories; For the treatment of iron deficiency anemia., Approved February 1999

Fragmin; Pharmacia & Upjohn; Treatment of prophylaxis of deep vein thrombosis (DVT), Approved March 1999

Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer; Treatment for acute deep vein thrombosis, Approved January 1999

Drugs Approved in 1998

Actonel; Procter & Gamble, Hoechst Marion Roussel; Treatment for Paget's Disease, Approved April 1998

Droxia; Bristol-Myers Squibb; Treatment for sickle-cell anemia, Approved March 1998

Glucagon; Eli Lilly; Treatment for severe Hypoglycemia, Approved September 1998

Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer; Treatment for prevention of blood clots following hip-replacement surgery, Approved February 1998

Neupogen; Amgen; Treatment for slow white blood cell recovery following chemotherapy, Approval April 1998

Refludan; Hoechst Marion Roussel; Treatment of heparin-induced thrombocytopenia type II, Approved March 1998

Drugs Approved in 1997

Agrylin (anagrelide HCL); Roberts Pharmaceutical; Treatment for thrombocythemia, Approved March 1997

BeneFIX (coagulation Factor IX (recombinant)); Genetics Institute; Treatment for hemophilia B, Approved February 1997

Glyburide Tablets; Roche; Treatment for blood-glucose lowering, Approved December 1997

Glyburide Tablets; Mova Pharmaceutical; Generic version of Glynase PresTab, Approved December 1997

Lovenox (enoxaparin sodium) Injection; Rhone Poulenc Rorer; Treatment for deep vein thrombosis, Approved May 1997

Neumega; Genetics Institute; Treatment for thrombocytopenia, Approved November 1997

Rituxan; Biogen IDEC, Genentech; Treatment for non-hodgkin's lymphoma, Approved November 1997

Drugs Approved in 1996

AlphaNine SD Coagulation Factor IX (Human); Alpha Therapeutic Corporation; Treatment for the prevention and control of bleeding in subjects with hemophilia, Approved July 1996

Gastrocrom Oral Concentrate (cromolyn sodium); Rhone Poulenc Rorer; Treatment for mastocytosis, Approved April 1996

Leukine (sargramostim); Immunex; Treatment for the replenishment of white blood cells, Approved November 1996

Nascobal Gel (Cyanocobalamin, USP); Questcor Pharmaceuticals; Treatment for vitamin B-12 deficiency, Approved November 1996

Pravachol (pravastatin sodium); Bristol-Myers Squibb; Treatment for cholesterol-lowering, Approved July 1996

Visipaque (iodixanol); Nycomed; Diagnostic contrast agent, Approved April 1996

 

Kidney & Urology Foundation of America | 152 Madison Ave, Suite 201 | New York, NY 10016 | 1.800.633.6628
©

About Us | Patient Resources | Professional Resources | Support Us | News & Recent Events | Brochures
Corporate Sponsors | Contact Us | Terms of Use | Privacy Policy

Website Last Modified: October 28, 2010
Donate Today Donate Your Car Join KUFA Now